Metastatic colorectal cancer treatment drug furanitini capsule (Aiut) approved for market launch

today (September 5), the NationalDrug(Supervisory Authority announced that it has approved the treatment of metastatic colorectal cancerdrug(eaut) for previous chemotherapy for fluorouretics, oxalyp and Ilitocon-based chemotherapy, as well as previously accepted or unfit to receive anti-vascular endothelial growth factor (VEGF) treatment, anti-epidermal growth receptor factor (EGFR) treatment of colorectal cancer (EGFR)on furaninib is understood to be a targeted cancer treatment drug developed by Hutchison WhampoaPharmaceutical(Shanghai) LimitedCompany ((Shanghai)("Chi-Med), and is a niobium small molecular angiogenesis inhibitor, the main target of which is the VEGFR family of fritase (VEGFR1, 2inhibit the proliferation, migration and tube cavity formation of vascular endothelial cells by inhibiting VEGFR phosphorylation and downstream signal transduction on the surface of vascular endothelial cells, thereby inhibiting the formation of new blood vessels in tumors, and finally exerting tumor growth inhibitionHutchison Whampoa published the results of a 3-stage study of randomized, double-blind, placebo-controlled, multi-centered furanitinib for advanced colorectal cancer in theof the ASCO2017Conference (and in JAMA, June this year), with 416 previous cases receiving more than two rounds of systemic Patients with metastatic colorectal cancer in China with chemotherapy were given psilocyandine and placebo treatment in groups of 2:1, with the main end points of the study being total survival (OS), and the secondary end sympathising were no progression (PFS), objective remission rate (ORR), disease control rate (DCR) and safety evaluationadverse reactionsdata show: furanitinos 9.30 vs 6.57 months, mPFS 3.7 vs 1.8 months;